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Abstract: Prosthetic technology for people with missing limbs has made great progress in recent
decades. However, acceptance rates and user satisfaction are not only dependent on technical aspects,
but also to a great extent on social and psychological factors. We propose that these factors should
receive greater attention in order to improve prosthetic care and give recommendations how to
incorporate the findings from social science in research and development (R&D) and in care practice.
Limited access due to high costs of new prosthetic technology combined with rising costs in health care
systems in general is a further issue we address. Our legal and ethical analysis of the reimbursement
process in Germany shows that this issue requires further empirical investigation, a stakeholder
dialogue and maybe even policy changes. Social science knowledge and participatory methods are of
high relevance to answer questions about the benefit of prosthetics for users, based on individual
needs and preferences, which should be at the core of debates on ethical resource allocation.
Keywords: prosthetics; disability; reimbursement; regulation; HTA; ELSI; (just) resource allocation in
health care; clinical practice guidelines; equity; inclusion
1. Introduction
Artificial limb prostheses have become more sophisticated, with improved performance
and decreased weight due to the use of latest material science and engineering technologies.
Nevertheless, acceptance and usage rates vary strongly between different patients. While performance
is one acceptance factor and may be objectively measured, there are more subjective factors relating
to social aspects that appear to strongly influence the single person in his or her attitude to accept or
reject the use of an artificial limb1.
1 This paper was developed within the project INOPRO (Intelligente Orthetik und Prothetik für eine verbesserte
Mensch-Technik-Interaktion), funded by the German Federal Ministry of Education and Research (Bundesministerium
für Bildung und Forschung, BMBF). The overall aim of this project is to develop intelligent limb prostheses and orthoses,
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An important research aim of ours was thus to produce an overview of social acceptance factors
from the literature. As a focus for the present article, we selected the cost factor, as an international
study [1] found that it has a high impact on usage rates and satisfaction of users. The authors of this
study had concluded that analyses of national legal frameworks and empirical studies in different
countries are needed to better understand the situation of prosthetic care with regard to reimbursement
matters. Accordingly, our second research question for this paper was how the German reimbursement
system works for prosthetics and whether injustices with regard to access might result from it.
The consideration of costs of prosthetics leads inevitably to the ethical problem of health care
resource allocation and rationing in general. In this respect, Germany is a particularly interesting case:
Explicit, open rationing of health services based on cost-effectiveness analysis is avoided for ethical
reasons in Germany [2] but not in other countries [3]. However, ethicists think that explicit rationing is
inevitable in the long term also in a rich country such as Germany and that it is in any case preferable
to implicit rationing [3–5]—which, as a matter of fact, already taking place in many ways also in the
German health care system [5].
In the present article, we discuss two basic alternative solutions for the resource allocation problem
(which may however be combined in reality). The first solution would be to make prosthetic care
more efficient in order to alleviate the financial burden from health care systems (and individual
users in case their insurance does not reimburse the whole price). Here, we ask how this could be
achieved. The second solution would be to find just processes and criteria for explicit rationing.
One key prerequisite would then be to assess the benefit of prosthetics, ideally in an objective way,
set it in relation to costs, and at the same time incorporate individual, subjective user preferences and
needs into the equation.
With respect to the latter, we specifically ask which role Health Technology Assessment (HTA)
could play to help meet this requirement. HTA is a branch of Technology Assessment (TA), which is
exclusively concerned with health technologies, and has its very specific and own methods, functions
and institutions if compared to other areas of TA. There is a worldwide network of national HTA
institutions today (Health Technology Assessment International, HTAi). In Germany, the IQWiG
(Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, i.e., Institute for Quality and
Efficiency in Health Care), assesses mostly pharmaceuticals, but also medical devices. Benefits are
assessed in comparison to an existing, standard treatment for the same medical indication, in order to
inform policy and other decision makers about the additional benefit of new products, and also as
a basis to negotiate prices between manufacturers and the insurances [6]. The evidence base which
is used to assess a new treatment option are clinical studies, which analyse what effects relevant to
the patient, if any, a medical device or pharmaceutical has, for example for the patient’s quality of
life, a blood parameter, or the capability to walk or grasp objects. The methods used for HTA reports
are similar in different countries, but their function may differ according to the national regulatory
framework in place [7].
The paper is structured as follows. Based on a review of some of the most important social factors
for acceptance and successful use of prosthetics, as found in the social-scientific and psychological
literature (2.), we make some recommendations for an improvement of prosthetic care (3.). We then
(4.) give an overview of the reimbursement process for prosthetics for upper and lower limbs in
Germany and discuss ethical implications of this process. This overview is based on documents from
online sources, grey literature and academic publications from several disciplines (law, social sciences,
prosthetic care research, HTA, health ethics and economics). Concluding the paper (5.), we reflect on
the role of HTA and more generally value or benefit assessment of prosthetic technology and care for
reimbursement decisions.
which improve the quality of life of its users by more intuitive human–technology interaction, whilst ethical, legal and social
aspects are researched in order to increase acceptance and distribution of new prosthetic technologies.
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We will argue that prosthetic care is so important for the overall health of users that it is
economically beneficial for health insurances to deliver the best possible care. This has already been
pointed out in some studies [8,9], but is still not widely acknowledged by insurances, in Germany also
due to the short-term budget allocation scheme in the health care system [10] (p. 61). We posit that
there are ways to efficiently improve prosthetic care, minimising the burden on the health care budget,
in particular social aspects of acceptance are taken more systematically into account.
Furthermore, we argue that the current reimbursement process for prosthetics in Germany is
prone to injustices, and that a stakeholder dialogue is urgently needed to approach this issue. As a
starting point for this dialogue, we propose ideas for a role of HTA in the processes and adapted ways
of cost and effectiveness evaluation of prosthetics and assessment of individual needs and preferences
of its users.
2. Social Acceptance Factors
In the following, we will review acceptance factors for prosthesis use from a social
science perspective, i.e., beyond pure technical performance measurements. We will then draw
recommendations from this research for improvement of prosthetic care.
2.1. Social Environment
The acceptability of assistive technology is dependent not only on its efficiency, but also on
the reactions it elicits in people surrounding the user, as people with limb loss themselves have
rated social outcomes as more important for assessing quality of life outcomes than their physical
impairment [11,12]. Good social support has been identified as a predictor for not only the perceived
quality of life, but also the functional outcome after amputation [13,14]. The very definition of disability
is highly dependent on the environment defining this term, which further solidifies the need to pay
more attention to a patient’s surroundings and their place therein. People with limb loss reported
that they experienced a “disabled” identity mostly through the reactions of others [15]. Perception of
functional outcomes in relation to prostheses use have repeatedly been linked to the social environment
of a patient, with higher satisfaction and lower anxiety levels if prosthesis users felt accepted by their
social surroundings [16–18]. Therefore, the understanding of the social realities of prosthesis users
does not only allow for more empathy, but it can maximise the potential for positive outcomes of
prosthesis fitting [13].
2.2. Psychosocial Adjustment, Expectations and Personal Significance
When trying to assess factors related to prosthesis usage, the overarching theme of potentially
traumatic limb loss needs to be addressed. The experience of losing a limb, through either trauma or
disease, can have a significant impact on a person’s psychological reality. In addition to, potentially
significant, pain, people with limb loss commonly experience reduced self-worth, heightened anxiety in
social situations, depression, and even post-traumatic stress disorder [19]. Thus, how well people adjust
to the experience of limb loss itself has a significant impact on their ability to later accept and integrate
a prosthesis into their lives [13,15]. Psychosocial adjustment is defined as an individual’s response
to events having a significant impact on their lives, which require adaptation. Influential factors on
positive psychosocial adaptation have not been explored widely [20], despite the fact that it seems like
this adaptation is one of the most powerful facilitators of later prosthesis use and a high quality of
life [12,20,21]. There is, however, some evidence that factors such as an active coping style, as well
as general (dispositional) optimism, a tendency for “downwards social comparison”, as well as the
feeling that one has some control over one’s own situation, are all favourable indicators for good
psychosocial adjustment [15,22]. Widehammar et al. hypothesised that the care patients receive in early
rehabilitation stages can be a significant contributory factor to the development of effective coping [12].
Thus, this specific goal might need to receive more attention in mainstream rehabilitation protocols.
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Expectation management is another factor of vital importance in early rehabilitation stages.
Several studies found that setting realistic expectations is not only important to avoid disappointment,
but that there is also a positive correlation between meeting the initial expectations that users had
and reported satisfaction at later stages [17,23–25]. However, the degree to which this is practiced
appears to be insufficient at times. Interview participants in a study by Uytman mentioned that they
felt insufficiently informed about how quick their progress would be [26].
On the other hand, one important and often overlooked factor is the enthusiasm that can be created
by providing a patient who lost a limb with a functional replacement [15,27]. Experiencing positive
change in their abilities might actually be the first step to install a positive feedback cycle that in the
end leads to a successful incorporation of the prosthesis into their lives. If initial positive experiences
are reinforced and kept in focus, users can be more motivated to continue training with their devices.
The plus in experience in operating the prosthesis in turn leads to a more natural way and ease of
use, encouraging users to keep expanding the repertoire of activities they can facilitate with their
system. Murray found that such positive association is frequent if users see their prosthesis as an
enabling tool for valued activities that they associate with their personality [17]. These can be of social
nature, such as participating in dance classes or going out to clubs at night, playing with or helping
their children, or enabling greater proficiency at their workplace. Users who place special emphasis
on their autonomy are likely to integrate a prosthesis into their lives successfully if they make the
experience that the device can enable them to perform more tasks without the help of others. One of
the experiences that has been rated as one of the most liberating in connection with both upper and
lower prosthesis use is driving a car, which most users experienced as highly valuable [12,16,28].
2.3. Individual Choice of a Prosthesis and Communication with Prosthetists and Peer Networks
Research focussing on the relationship between user and prosthetist has found that good
communication between the two is a key factor in facilitating favourable outcomes [22,29–31].
Recognising that shared decision-making requires input from both sides could thus be a first step to
facilitate better relationships between the users of prostheses and those who provide them.
Especially, individual choice of the prosthesis itself is one of the few factors that have consistently
been found to be important for prosthetic acceptance [32]. Biddiss and Chau point out that users
who were involved in the selection process for their system are eight times more likely to continue
to use it later on [33]. One reason for this is certainly that users have different priorities and goals.
Whilst some users value function and reliability, others appreciate aesthetically pleasing design features
or customisable prosthetic covers [18,20]. These personal values will not only affect which type of
prosthesis users will find particularly useful in their everyday life. They also have a strong impact on
the emotional associations that they have with specific systems [20].
As lack of involvement can lead to issues if patients later feel that the decisions made were not the
right ones, recognising one’s own responsibility to partake in decision-making is one important step.
To aid in this collaborative endeavour, a prosthetist should always provide as much information as
the user needs to make an informed decision about the choice of the prosthesis and other steps in the
rehabilitation process. Research has shown that health care professionals frequently underestimate just
how much information patients need or desire for this purpose [29,30], so a heightened awareness of
the vital role this knowledge transfer plays would likely improve outcomes favourably. Not only does
the mere involvement of patients in the prosthesis selection process in itself produce higher instances of
continued use, but good communication between prosthetist and user is also the basis for many other
factors related to the successful integration of a prosthesis into a user’s life. This entails, for example,
setting realistic expectations, taking goals and wishes into account, encouraging users to persevere
through the initially frustrating training phases, as well as providing a stable and trusted fix point in
case issues emerge.
However, it is worth considering that the relationship between a prosthesis user and their health
care professionals cannot always provide the support, reassurance and knowledge exchange that
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the patients desire. Thus, other, more experienced prosthesis users can be an invaluable resource.
Gallagher and Maclachlan found that contact with other users of prostheses at an early stage after
amputation can greatly enhance patients’ confidence by reassuring them that initial uncertainties and
difficulties are normal and can be overcome [25]. The participants in their study who were given such
an opportunity all rated it as highly beneficial, and others expressed they had wished to be given
the possibility to do so. Given that prosthesis acceptance seems to be a long-term process, meeting
someone who can confirm from first-hand experience that mastering one’s system is doable and worth
it can install confidence and hope in new users [15,28]. The participants in Hamill et al.’s study rated
the exchange with others who had gone through the same experience as their strongest “support
connection”, seeing them as persons whom they could consult with respect to questions they might
have felt uncomfortable to ask the medical staff.
3. Improvements of Prosthetic Care from the Perspective of Social Science Research
It is important to translate knowledge about social acceptance factors into practice. By doing so,
probably not only quality of life may improve but also resources may be allocated more efficiently by
reducing long-term negative side effects of failed prosthetic care such as a lack of acceptance of and
adaptation problems with prostheses as well as by reducing costs in its research and development
phase. It has already been shown, for example, that prosthetic care for high-cost knee prostheses
is beneficial for the insurance budget in the long term, if compared to the use of such prostheses
without care [8,9]. Biddiss et al. point out that there are possibilities to reduce costs of prosthetic
limbs by technical means like computer-aided design and manufacturing, and due to new market
opportunities [1]. In recent years, this aspect already received significant attention in the media
where technical means of rationalisation are often focused. 3D printing, for example, is expected to
increasingly provide solutions for bringing prosthetic care to poor world regions. We think there might
also be chances to improve prosthetic care in Germany and make it more efficient by giving social
research a more relevant role. In the following, we will describe further specific recommendations
with regard to both, current practice and future research directions.
3.1. Development of Prosthetic Technology
Patient engagement in the development of new therapies is an important pillar of translational
research [34]. Recently, this kind of “citizen science” or “patient science” has been increasingly
promoted and supported by policy makers and others. However, it is well known from biomedical
research that it is challenging to make use of experiential knowledge in the research and development
(R&D) process [34]. Methodically, it is challenging to give users a rich impression of what the innovation
could look like. Furthermore, it is difficult to link the experiential knowledge of users to the envisioned
innovation [34].
In respect to the development of prostheses, developers indicated that there are relatively few
opportunities for them to communicate directly with users about prosthesis design and functionality [35].
Studies about user preferences and wishes regarding prosthesis design and functionality do exist,
but sometimes have limited validity for direct implementation in practice, for example when only
doctors are asked on users behalf [36]. Also, in qualitative and explorative studies users with diverse
kinds of amputations and models are asked about limitations of prostheses and design priorities
without dividing them into subgroups due to the small number of participants [37]. Generally, however,
such studies can deliver valuable guidance for R&D in order to improve usability and usefulness
of prostheses. There are different ways of asking about preferences and development needs, from
direct and open questions about wishes of users in qualitative studies via more indirect and less open
investigations. These may include research into functional (technical) rejection factors, the ranking of
suggested features which should be improved [37] and of the relevance of daily tasks which are difficult
with current prostheses [38,39]. For prosthetic technology which bears a risk, e.g., invasive control
techniques, questions about the acceptance of trade-offs of functional benefits and invasiveness may be
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asked [40]. Open questions about wishes may bring new ideas and perspectives into development.
However, a limitation of this kind of questioning may be that users acquire an attitude of being
satisfied with the status quo. In addition, some developments that are planned by innovative prosthesis
makers may not occur to users and, when they are presented for evaluation in a questionnaire, may be
unimaginable for users when they cannot test a prototype. As Benz et al. put it, “it is difficult for
users to map technical advances or specific device features to their individual experiences with a
prosthesis“ [37] (p. 288). A more regular interaction of developers and users is needed, and in different
steps of the development process. During the course of a prosthesis development project, numerous
design and functional decisions are being made every few weeks or months. However, users are often
only indirectly, if at all, incorporated in these decisions. They may then only asked to test demonstrators
when months of work have already been invested for the development; and product descriptions are
often too vague for users to evaluate the prostheses in a valid way. Generalisability increases with the
diversity of test users, and shorter cycles of iterative user feedback and progression in the development
can diminish the gap between users wishes and developers imagination.
3.2. Cooperation between Professions in Research and Practice
There is a need for more communication between professions within prosthetic care. For example,
it has been pointed out that systematic research by prosthetists would be important, but is rather
done in clinical settings or by researchers who are themselves no practitioners in the field [41].
The British Association of Prosthetists and Orthotists describes the contribution to research as an
explicit and mandatory role of prosthetists [42] (p. 3). Research conducted by practitioners would
help to represent real-world settings like patient diversity in a study as closely as possible and thus
increase generalisability. An established research culture within practice at the same time makes sure
that results are noticed by practitioners and implemented more widely. The direct communication of
acceptance research results to the practitioners might also be an option. In any case, more exchange of
expertise is needed between social science and acceptance researchers on the one hand and prosthetists
on the other.
3.3. Guidelines
Besides informal communication channels from practitioners to researchers and back, systematic
research results may also reach practice via CPGs (Clinical Practice Guidelines).
Numerous such CPGs can be found published online for different kinds of prosthetic care,
providing advisory information for practitioners. For example, for knee prosthetics there is a CPG
informing about the specific advantages of microprocessor-controlled vs. other prosthetic knees and
conclusions that can be drawn for knee selection for a user [43]. This information can guide the
decision of the doctor whether a user might benefit from microprocessor-controlled knees. CPGs are
used as guides for prescription choice (e.g., also [44]), but can also include more detailed best practice
recommendations for all phases of rehabilitation and its organisation [45] (pp. 6–7), [46] (pp. 55–56).
CPGs tend to be rather heterogeneous guideline documents [47], which may be produced by (national)
medical associations and health organisations or departments [45,46,48], but also othe players in the
health care system such as hospitals [43,49] and insurance companies [44]. In any case, they are not
binding for care providers however. Different methods may be used to create CPGs, including Delphi
surveys with professionals [44,48] and focus groups with patients [45,46]. It would be desirable to
have (nationally standardised) guidelines covering all aspects of prosthetic care and amputation types,
using input not only from practitioners but also users.
The basis of CPGs is mostly evidence according to standards of HTA and practitioners’
experience [50] (p. 5). With respect to Germany at least, we think that there are options to improve
prosthetic care by taking research on social acceptance factors more systematically into account in
guidelines for such care. At present, some socio-psychological aspects already receive attention in
some guidelines [45,46]. A German guideline on amputation of lower limbs, for example, states that
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the user and not its stump should be at the centre of rehabilitation and that the social environment
should be included in the rehabilitation process [48] (p. 15). It also recommends to evaluate quality
of life of users and support psychological coping mechanisms [48] (p. 21). These incorporations of
socio-psychological aspects in current CPGs are a significant improvement if compared to simple
prescription guidelines focusing solely on physiological and technical aspects—but they are still not
very detailed or a very prominent part in the guidelines.
Guidelines could address the criteria for an adequate individual choice of a prosthesis by taking
into account personal factors other than age, physiology and activity levels, such as the extent to
which a user values aesthetics. While for prosthetists, this knowledge is acquired during practice
and can be transmitted from experienced to less experienced prosthetists, doctors might be not so
much aware of these important acceptance factors. The latter have to prescribe prostheses but are
not involved in the following supervision of their use, although it is of crucial importance, also with
regard to reimbursement, that they prescribe the “right” prosthesis in the first place. Last but not
least, CPGs could also address communicational aspects of care such as the frequency of informational
exchange with the prosthetist, or the opportunities of access to peer networks (as is the case in one US
guideline) [45] (p. 76).
3.4. Education and Training of Professionals
We already mentioned the benefits of practicing prosthetists being able to do research or work
with researchers conducting evaluation tests with individual users [42] (which may entail outcome
assessment as a task for prosthetists). In order to reach their intended audience, the results of
social science research on prosthetic care should be included in education curricula for prosthetists.
They accompany users from the first fitting process on, and sometimes in their entire future life,
as changes in prostheses or fitting of new prostheses have to be done every few years. It is self-evident
that prosthetists should thus be aware of all relevant acceptance factors like social factors and
psychosocial adjustment processes in order to help the user, for example with prosthesis choice and
adaptation processes. Research results that are so far rarely used in everyday practice could be an
additional helpful resource of knowledge for them. Also, the British Association of Prosthetists and
Orthotists names integration of best available evidence into practice as an explicit and mandatory role
of prosthetists [42] (p. 3).
In Germany, the usual qualification of a professional prosthetist is not an academic but a rather
practically and technically oriented trade education. The few academic courses (Master) on prosthetics
have a strong focus on engineering. Therefore, there is a kind of professional gap of acceptance
and understanding between the more hands-on prosthetists and the engineers with a university
background. Thus, it would make sense to incorporate a more interdisciplinary approach, including
optional courses on psycho-social aspects, in the education of German prosthetists that may allow for a
more holistic view of prosthetics and the users of prostheses.
3.5. Peer Networks
With regard to the reimbursement issue, users can inform each other about their experience and
help to distribute the knowledge about insured user’s rights more widely. Peer networks created
via online tools, events in prosthetic care houses or personal mediation can bring users together.
This is however only a work-around for a profound regulatory, ethical and communicative problem
that should be discussed between all stakeholders including developers and users, policymakers
and insurances.
Peer networks are also invaluable for informing users about prosthesis choice. Not only the
pros and cons of different prosthesis types but also personal accounts of more experienced users can
generate more realistic expectations. Health care professionals cannot always provide the support,
reassurance, and knowledge exchange a patient desires. In some cases, patients even reported some
reluctance to ask the medical staff about the consequences of amputation if they felt like the question
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might be “stupid” or if the answer might be frightening and unpleasant to cope with [15,22]. Within a
peer-network however, asking an individual who has already dealt with these topics first hand might
reduce the initial hurdles to address them. As such, participants of Hamill et al.’s 2010 study rated
other individuals with limb loss as the most credible source of information regarding the consequences
of amputation due to their status as “insiders” with personal experience [15]. They act as a role model
and guide others.
3.6. Communication between User and Prosthetist
Good communication between the prosthesis user and their prosthetist is vital, as important
decisions such as which prosthesis model to choose, how to optimise them for the individual user,
as well as the kind of training required, are made between the two. However, not all patients favour the
same level of involvement. Ideally, all decisions should be made collaboratively, taking into account
the patient’s wishes, as well as considerations about what is medically feasible. However, especially
new users might struggle with partaking in the decision-making process due to the gap in knowledge
and experience. To enable patient-centred decision-making models, communication between patient
and medical staff needs to be effective and informative enough to grant patients access to relevant
information surrounding the decisions to be made. Most prosthesis users have a strong interest in
finding the best long-term solution for their specific case and all communicative efforts to enable this
best possible solution should be made.
3.7. User Choice
Acknowledging patient preferences is a general aim in health care and should also be taking into
account for prosthetics [51]. The kind of physical activities a user would like to engage in, as well as the
wide range of subjective rehabilitation goals users might have, can have a significant impact on how
appropriate a certain type of prosthesis might be. Prosthesis users should be able to choose between
several options based on their knowledge of the drawbacks and benefits of a specific prosthesis in
combination with their own preferences and goals. Ideally, this knowledge is acquired by testing
the prosthesis for a sufficient time period, but could be substituted for the best available information
provided by a prosthetist and other users.
4. Cost as an Acceptance Factor and Access to Prosthetic Care in GERMANY
In the following, we will point out that cost is an important acceptance factor for prosthetics besides
technological, social and psychological factors, and make a deeper analysis of the legal background
and ethical implications of the reimbursement process in Germany.
4.1. Cost as an Acceptance Factor
An international study on the role of affordability in selection and wear of upper-extremity
prostheses showed that 37% of prosthesis wearers were not fully reimbursed for their expenses and that
48% of non-wearers considered the cost an influential factor in their decision not to wear prostheses [1].
The survey results also suggest that prostheses are sometimes selected based on affordability and
that multiple device access is highly appreciated but also dependent on financial support [1]. Fear of
damage and resulting repair costs were cited by 34% of those who reported reasons for non-wear,
which can hamper participation in social life and activities [1].
The fitting time is another acceptance factor which may be relevant independently from the
reimbursement process but is often directly linked to it. In case of procedural hurdles for getting a
prosthesis reimbursed, the insured may choose not to buy a prosthesis at their own expense in case
their application fails. This may lead to a considerable time lag between the prescription and first use
of the prosthesis of several months. In this context, it is relevant that early fitting both for congenital
and acquired limb loss seems to increase the prevalence of sustained prosthesis wear [18,33,52–55].
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Biddiss and Chau found that users who were fitted within six months of amputation were 16 times
more likely to continue use than those fitted later [33].
As systematic data for reimbursement of prosthetics in Germany is missing, it is difficult to
estimate the scale of this issue. We do however have anecdotal evidence from conversations with
prosthesis users, as well as prosthetists and device producers, which leads us to assume that the problem
of insufficient reimbursement and a lack of transparency still exist. Some years ago, the reimbursement
process has already been discussed as one important factor to be improved for optimized care with
medical aids by the German Association for Rehabilitation [56]. It was stated by professionals in
the field that there is unequal treatment in reimbursement or prosthetic legs [57], that claims for
medical aids, in general, are intransparent and may require high extra payments for the insured [58].
Thus, studies are needed to systematically analyse the scale of this issue. Biddiss et al. recommend
the conduct of empirical studies in other countries to analyse the specific national reimbursement
regulations [1], which we will do now.
4.2. Reimbursement Practice and Regulation
Paving the way back into everyday life after amputation requires collaborative efforts between
the amputees, their social circle and different professional groups such as doctors, physiotherapists,
nurses and orthopedic technicians. Other actors to consider are case reviewers and employees at the
responsible insurance companies. The prosthetist is probably the most central person for the amputee:
He or she will accompany them during rehabilitation and will remain the decisive contact person and
confidant later on. The prosthetist is in charge of all aspects of prosthetic care, such as suggesting
specific models, as a large number of different prostheses and individual components are available.
The prosthetist is also at the interface between doctor, health insurance company and the patient.
They prepare a cost estimate based on the medical prescription, which has to be approved by the
responsible health insurance company.
On the legal side, the situation in Germany is quite complex [59]. The Federal Participation
Act (Bundesteilhabegesetz) is intended to implement the UN Convention on the Rights of Persons with
Disabilities. It is intended to enable people with disabilities to participate as fully as possible in all
areas of society. Furthermore, reimbursement of medical devices is regulated in the Social Code Book
(SGB, Sozialgesetzbuch), according to which those covered by insurance are entitled to the provision
of aids, including prostheses, “in order to ensure the success of the medical treatment, to prevent an
impending obstruction or to compensate for a disability” (§ 33, Abs.1 SGB V). Aids to compensate
for a disability are covered by § 33 SGB V if they are needed to satisfy the basic needs of daily life.
The Federal Social Court (Bundessozialgericht, BSG) has defined the following activities as basic
needs: Walking, standing, sitting, lying, grasping, seeing, hearing, excreting, eating, basic body care,
independent living, as well as the development of a certain physical and mental freedom [60]. Claims to
statutory health insurance providers are also based on the so-called economic efficiency principle, i.e.,
they are limited to those measures which are to be regarded as sufficient, expedient and economical
according to objective standards, as well as not exceeding the measure of what is necessary (§12,
Abs.1 SGB V). Practically, the BSG states that considerable additional costs for a more modern and
state-of-the-art prosthesis do not play a role if there are advantages compared to the previous prosthetic
care. Rejection solely on the grounds that a medical aid is too expensive is not permitted by law.
“Significant additional costs are only relevant if the additional benefits of using a new aid in everyday
life are rather low and the associated costs are disproportionately high compared to a standard of care
that has previously been considered sufficient” [61]. To prove that a user actually is able to benefit
from a prosthetic, typically a video or personal demonstration is given to the health insurance fund or
the Medical Service of the Health Insurance Funds (Medizinischer Dienst der Krankenkassen, MDK).
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4.3. Ethical Reflection on the Legal and Practical Reimbursement Situation in Germany
It may occur that insurances reject the initial application for a prosthesis. The reasons they give
for a rejection are contradictions in the prescription of the doctor and the demand of the insured,
or insufficient explanation of the needs of the insured and of why the prosthesis chosen should meet
these needs. The insured can then appeal and the insurance can review its initial decision. If the review
does not lead to a revision of the decision, the insured has the possibility to file a lawsuit against
the insurance at the social court. In the majority of cases, the social courts decide in favour of the
insured [62,63]. However, costs for a lawyer have to be paid by the insured [63] and financial and
administrative hurdles in the reimbursement process may represent a considerable or even decisive
barrier for people in need of prostheses. Especially in cases where the reimbursement decision is made
in social court, laborious paper work and emotional distress can be expected. To buy a prosthetic
without insurance can cost as much as several tens of thousands of Euros and they are thus not
affordable for a large part of the population. From an ethical perspective, there are two strands of
arguments that call for a change of this situation.
The first is that disabled persons should have equal chances to pursue a life in dignity and to its
full potential. There are a number of literature studies that show how important a successful prosthetic
rehabilitation can be for reestablishment of a positive body image, self-esteem and reintegration in
social life [12,13,18,27]. Studies show also that a significant percentage of people with acquired limb loss
have difficulty returning to work, and those who do usually require job modifications to be successful,
and use and acceptance of upper limb prosthetics are positively correlated with employment [64] (p.
114). Special sports prostheses are mostly not reimbursed, based on the argument that sports is not a
basic need, especially when the user did not do this sport before his/her amputation. However, it is
obviously an important part of many people’s lives and grants quality of life, and also health, and may
be an important aspect of social inclusion. Thus, criteria such as need and equity should play a bigger
role in addition to benefit and efficiency considerations for reimbursement decisions. These principles,
ranked in importance in the order from need to benefit to efficiency, should be balanced, though it is
difficult to generalize how exactly they should be balanced or weighted [4].
In 2007, the German Central Ethics Commission on medicine (Zentrale Ethikkommission, ZEKO)
drafted recommendations on just criteria for prioritisation of health care, followed by the German
Ethics Council (Deutscher Ethikrat) in 2011. Prioritisation means that certain medical indications or
people are preferably treated due to cost and/or medical effectiveness reasons. Explicit rationing on the
macro-level of the health care system (e.g., denying reimbursement of an expensive cancer treatment
for all patients, or a group of patients with specific medical characteristics) is avoided in Germany
based on ethical grounds. Prioritisation is however implicitly taking place also in the rich German
health care system, through individual prescription decisions doctors, or, as in the case of prosthetics,
reimbursement decisions by state insurances.
The criteria the ZEKO recommends with regard to the process of prioritisation are transparency,
justification, evidence-basedness, consistency, legitimacy, openness and balance of conflicts of interest,
legal protection, and regulation [4]. For prosthetic care, there are strong hints that the criteria
transparency/openness, justification/legitimacy, evidence-basedness, and consistency are not fulfilled.
Initial rejections of the reimbursement applications are not justified in every case, as a considerable
number of insured in need of a prosthesis go to social courts and win the lawsuit against their insurance.
It can be assumed that there is also a high number of insured who do not veto the initial insurance
decision, which leads to unequal access based on the capability to seek legal aid. It can also be
doubted that decision criteria for the initial rejection or approval of reimbursement of prostheses
are consistent across all insurances within the state-funded insurances in Germany (Gesetzliche
Krankenversicherungen, GKV), as they have their own service catalogues. Thus, it cannot be excluded
that certain groups of insured are discriminated against with regard to access to prosthetics. Starting in
2017, the medical aid catalogue will be reworked/updated based on scientific evidence and quality
criteria by the GKV according to the Gesetz zur Verbesserung der Heil- und Hilfsmittelversorgung [65].
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Also, insurances are obliged to inform insured better about their contract details on medical aids.
However, this law does not touch the decision capacity of insurances based on individual cases and
according to their internal rationales, improving little if at all the transparency and evidence-basedness
of reimbursement decisions.
Discussions about the question whether it is ethically justified to ration health care at all are
very controversial. Some politicians even condemned proposals of this sort as against human dignity.
However, it has also been argued for a long time now by ethicists that rationing is inevitable in the
long term and implicit/non-transparent rationing shall be avoided, and general ethical criteria for
rationing have been proposed [4,5,66]. However, the more serious this proposal is taken, the more
specific criteria have to be found for every health care item. As every spending drains resources from
another item in the health system, a systemic view is needed, and measures be found that make items
comparable (with regard to whatever criteria are chosen, be it benefit, cost, equity, need, or others,
and their relations).
Prosthetic care is a comparatively small financial item within the entire health care budget.
This does not mean that expenses are justified in any case, as this in a way would discriminate insured
who belong to groups affected by diseases, which are using a larger part of the health care budget. It is
beyond the scope of this article to discuss this broader ethical dilemma of just allocation of resources
in a health care system with limited resources. Public debate regarding the possibility of explicit
rationing or redistribution of federal budget may have to take place. The point we want to make here
is simply that currently, prosthetic care is implicitly rationed and therefore unfairly distributed in
Germany. The costs of a more fairly distributed prosthetic care in Germany (where everyone would
get the same chance to get an optimal prosthesis according to his/her needs) may be higher or lower
than current costs for prosthetic care (where some insured don’t get the prosthesis they want) is a
fairly open question. There are only few studies regarding this question for the US, suggesting that
in the long term, prosthesis prescription even could save money [9]. While Section 2 of this paper
dealt with the question of how prosthetic care could be made better by social innovation and changes,
but possibly at the same time more efficient in order to circumvent this problem to a certain extent,
we will now turn to the more complex question or an alternative solution. What would have to be
done if explicit rationing shall indeed become reality in the future, in order to conduct it in transparent,
just and evidence-based (and thus ethically justifiable) ways?
5. Health Technology Assessment (HTA) in the Reimbursement of Prostheses
In the following, we will propose directions for the evaluation of prosthetic care as one requirement
to solve the broader ethical problem of just resource allocation in health care systems.
5.1. HTA—Assessment of Costs and Benefits and the QALY Concept
General process and content criteria for prioritisation as defined by the German ethics committee
on medicine [4] are a first prerequisite to make reimbursement more just. Though it is contested how
and if at all, one can optimise the benefit across the whole population in a just manner, the effectiveness
of prosthetics should play some role for distribution of resources. After all, it is the primary goal
of health care to improve quality of life of people, and non-effective treatments will drain resources
from other areas of health care where people may benefit. The next and probably more laborious step
towards just reimbursement would thus be to find methods for effectiveness evaluation of specific
technologies. Biddiss et al. see the evidence-based evaluation of prosthetic practices and outcomes as a
prerequisite for reimbursement policy change [1].
Deciding about the reimbursement of prosthetics based on benefits and costs is in fact one (simple)
way of interpreting the criterion of being based on evidence, which the ZEKO defined. This refers to the
term “evidence-based medicine” (EBM), which stands for the principle to use the best evidence at hand,
ideally the statistically significant outcome of prospective randomized controlled trials, and summarize
it according to a certain standard systematically in order to inform approval decisions by regulatory
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bodies. An evidence-based evaluation has been suggested to be highly beneficial for prosthetic care
specifically, both to empirically justify prescription of high cost prostheses [67], but also to improve
quality and raise efficiency [41]. In Germany, evidence-basedness of reimbursement means that only
such medical treatments are reimbursed which have a benefit going beyond alternative treatments [2].
For pharmaceuticals, the benefit gain of the new treatment in comparison to existing treatments,
and their respective prices, are used to negotiate the price of a new treatment between manufacturer
and GKV [2]. This procedure has the advantage that nothing is being withheld from patients based on
costs, but still some form of limiting the rising costs for pharmaceuticals is achieved.
This limit is however quite arbitrary as the “starting price” for a specific indication is taken mostly
as pre-given and can basically be determined by the manufacturer who puts the first treatment for
a certain indication on the market [2,66] (p. 45). An assessment of benefit and costs of prosthetic
technology could be not only a quality and cost control mechanism within a specific health care sector,
but also a first step towards a comparability of treatments across sectors, like cancer and prosthetic care.
In the UK, there is now a regulation in place which sets a limit of Euros a Quality adjusted
life year (QALY, a measure of gains in both quality and length of life) may cost in order to be
reimbursable. Above a certain limit (around 25,000 £/QALY), reimbursement is not excluded but
demands specific justification [50] (p. 23). Though methodologically difficult, there are studies
asking the general public for their willingness to pay for one QALY, with the aim of democratically
legitimising such a number [68]. There are only few attempts to evaluate cost-effectiveness of
prostheses up to now. Two studies evaluating the same prosthesis came to very different results of
3000 vs. 35,000 Euros/QALY [69], which shows that it is still a methodological challenge to measure
QALYs, besides ethical objections [66] (pp. 64–65). But at least all three studies found Euro/QALY
amounts below the assumed Euro/QALY limit of the UK, a result that might suffice as a legitimisation
for reimbursement.
Whether a health care system uses an approach with QALYs like in the UK or negotiates prices
based on additional benefits of a treatment like in Germany, it is important to have an evidence base in
the form of reliable studies. Without scientific evidence, the uptake and diffusion of health technologies
is likely to be influenced by a range of social, financial and institutional factors, resulting in suboptimal
health outcomes and inefficient use of resources [50]. For prostheses, the evidence base is rather scarce
(for microprocessor controlled knees one can at least find several studies, see [69–71]), and only a few
HTA studies can be found for upper limb prostheses [72]. This may be a critical point explaining
insurance providers’ unwillingness to provide more expensive prosthetics. It also makes it difficult to
change regulations in a way incorporating the evidence-basedness criterion of the ZEKO and thus
make it more difficult for insurance providers to proceed with implicit rationing. One more option
would of course be to give insured access to prosthetics without any interference option by insurance
providers. The past has shown, however, that in a profit driven medical sector, this is in general not the
best option. Without quality control mechanisms like a systematic, manufacturer independent benefit
evaluation in place, it may result in high prices for medical products with low quality, thus worsening
the financial problems of the health care system and not necessarily fostering the development of good
products and patient care.
Also, while an inclusion of social aspects as discussed above might alleviate the health care
budget problem by making prosthetic care supposedly more efficient, this has to be assessed in some
objective way, e.g., by HTA, as well. We will consider prosthetic care evaluation from a broader,
multidisciplinary perspective rather than a narrow perspective focusing on (objectively measurable)
physiological parameters and direct costs of the prosthetic technology. This is why we come back to
our findings from the social science literature here as well.
Overall, we try to bring socio-economic/HTA, ethical and social perspectives on limb prosthetics
together in a so far unique way. Furthermore, we give some policy recommendations with regard to
starting the process of discussing the reimbursement process and regulation and possible changes.
Societies 2020, 10, 10 13 of 20
5.2. Hurdles for HTA-Based Reimbursement
There are three intertwined hurdles for developing HTA-based reimbursement criteria for
prosthetics. One is that guidelines or standards on evidence-based evaluation of prosthetic care
(and medical devices generally) are lacking so far [10] (p. 10). HTA agencies state that the available
studies they had to base their assessment on were generally small and methodologically weak [69].
The available number of HTAs is very low. Also, the studies which the HTAs are based on were
mostly sponsored by manufacturers and patients were often fit and healthy adults, which means a low
generalisability of results [69]. Outcome measures are heterogeneous and thus difficult to summarise
or compare between studies [71], and only some studies assess quality of life, but most of them rely on
functional outcomes like speed, balance, gait biomechanics, and energy expenditure [69].
One reason for the scarcity of clinical studies and HTAs is the legal framework for medical
devices in Germany and the EU. Medical products of low risk (class I and IIa), there is no obligation
for manufacturers to make a benefit evaluation at all [10,73]. The sole requirement to gain market
access is the CE mark which is basically a certificate for compliancy with safety standards [10] (p. 58).
The Federal Social Court (BSG—Bundessozialgericht) decided in 2015 that if a medical aid (prostheses
are also classified as medical aids, which is crucial for reimbursement regulation) is innovative,
insurances are not allowed to reimburse it without further investigations on benefit [74]. For new
prostheses that are not seen as “innovative” by the G-BA (Gemeinsamer Bundesausschuss), there is no
incentive for producers to conduct more studies on effectiveness than necessary for CE mark purposes.
Rather, this would be a financial burden and a risk in case of negative study results. Thus, to encourage
the conduct of studies according to standards of evidence-based medicine (EBM), a more demanding
legal framework is needed. At the same time, care has to be taken that small and medium-sized
companies (SME) are not overburdened with complex, costly and time-consuming requirements [10]
(p. 10). Currently, the framework in Germany is insufficient in this regard, and policymakers can
produce innovation impulses by helping to develop evaluation processes [10] (p. 11). The question of
who has to finance studies has also to be solved [75].
The third issue is that there are methodological difficulties with the evaluation of medical
devices in general, as they are characterised by complexity, incremental innovation and dependency
of effectiveness on the care provider (as discussed in depth in [73]). Medical device manufacturer
associations in Germany are calling for the development of scientific guidelines for a transparent
benefit evaluation of new medical products [64]. Otherwise, uncertainty and complexity of the
regulatory framework may hinder the realisation of new ideas in medical technology development in
Germany [10] (p. 11).
Methods and regulation of benefit evaluation should ideally be innovation-friendly, user-centred,
mirroring real-life care settings [76,77] and satisfying the demands of insurances who wish to legitimize
their decisions based on good evidence [75]. There is a huge breadth of possibilities concerning the
evaluation of prosthetics. One has to choose the point in time (before or after market access, right
after fitting or after a time period for letting the user adapt), number of users and prosthetic models
studied in every user, mode of study (registry or clinical study, case studies) and most importantly,
measurement instruments/outcomes.
The ZEKO gives only very general hints with regard to evaluation of prosthetic technology: Benefit
evaluation of medical treatments should be both evidence-based and patient-oriented, and evidence
has to be gained systematically [4]. A general conclusion from that is that it is important to include
quality of life as a criterion for reimbursement and not only a functional evaluation (as, for example,
asking whether the user is able to walk a certain distance with the prosthesis in a certain manner).
5.3. The Role of Social Factors for the Assessment of Prosthetics
Social acceptance factors interact with technical aspects of the prosthesis, as shown in the first
part of this paper. Thus, it is not reasonable to measure or predict benefit based solely on surrogate
parameters like functionality at a certain time point, only because they are easier to measure and
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quantifiable. Other non-quantifiable values like patient preferences, acceptability, equity concerns and
indirect benefits and costs should be accounted for in HTA assessments if they are used as a basis for
reimbursement decisions [50].
In addition, the context of evaluation can be crucial for the result. Opinions and experiences
of health care professionals and individual users are needed to understand the real-world benefit
of a technology [50]. For example, when a user has not been involved in choosing the prosthesis,
the evaluation result will be misleading regarding the potential of the technology (it would have in
an optimal care and social setting). Thus, social acceptance research is important to consider when
thinking about how, when, in which setting, and by whom prostheses should be evaluated to get
valid results that are transferable to future users. However, a conclusion might also be that prosthetic
care success is to such an extent individual and the context so decisive for the benefit of a prosthetic
technology that no prediction regarding an individual could or should be drawn from the general
population of users. If this is true, it might not be an unavoidable obstacle for prosthesis evaluation,
as wearing a prosthesis has no such acute or irreversible side effects as pharmaceuticals and implants.
Though social aspects of prosthesis acceptance are crucial, new technological developments
also have to be taken into account when thinking about policies of prosthetic evaluation and
reimbursement. Individual designs, e.g., with 3D printing of prosthetics (or Lego Limbs) can
boost acceptance and are assumed to contribute to a positive self-image, particularly in children.
The personalization/individualization of medical treatments which is discussed for medical substances
as a challenge for effectiveness testing methods [10] (p. 10), and there might be critical voices not
accepting this kind of aesthetic demands as medically strictly necessary. Further research is thus
needed on this specific aspect of aesthetics and related regulatory questions around individualized
medical products, both regarding safety [78] and reimbursement. Reimbursement regulation for
individualised medical products is generally complex and intransparent in Germany [10] (p. 11).
One approach would be a systematic evaluation with questionnaires conducted directly by the
care providers (doctors or prosthetists) and collected in registries. With regard to a suitable method,
a prosthesis evaluation questionnaire (PEQ) is available to measure quality of life of people with limb loss
and quantify the benefit of using a prosthesis [79]. It was used to assess one microprocessor-controlled
knee in a US study. However, in Germany, there are no medical registries for people with limb loss and
the authors could not find published studies using the PEQ. Tools like PEQ are needed and should be
validated further, as well as anchored in guidelines and teaching in prosthetics.
An individual evaluation per case by the care providers in this manner could open up possibilities
for testing a new and diverse set of prostheses for every user in order to make the best individual choice
and at the same time produce data that could be aggregated to generate more general conclusions
about benefits of specific prosthesis models for specific user groups. Testing the benefit of prostheses
under real-world conditions improves the reliability of the evaluation. Another advantage is the fact
that evaluation after market access is generally innovation friendlier. Products can be sold while
in the testing phase, users can get access to potentially beneficial technology, but at the same time
it is guaranteed that products without sufficient benefit are deselected based on the collected data.
Of course, safety-testing is still needed before market access. A drawback of this approach is that a full
evaluation for every user would need extra time resources on behalf of the prosthetic technician and
the user him/herself.
5.4. Early Stakeholder Dialogue and Implementation of Reimbursement Recommendations
We described a possible approach for evaluation and made reference to a validated method from
the literature here. However, this is only a suggestion, and pros and cons for this and other approaches
as well as combinations thereof (like randomized controlled trial combined with registry data [77])
have to be discussed by experts and stakeholders specifically for prosthetic care in our view. It has
been argued that HTA (of effectiveness/benefit) and regulatory evaluation (of safety) should be aligned
for medical products [75]. The German Academia of Engineering Sciences (ACATECH) recommends
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a collaboration of representatives of clinical medicine, industry and research, as well as regulatory
agencies to develop suitable guidelines for effectiveness/benefit evaluation of individualized medical
products [10] (p. 11), and patient feedback on the quality criteria used [10] (p. 64). For the case of
prosthetics, we would also suggest incorporating prosthetists besides users.
An important issue to think about would also be how to implement more standardised and
evidence-based reimbursement criteria once they are developed and consented on. The current
situation shows that there is a lot of uncertainty about the claims of prosthetic users. In the future,
this uncertainty should be avoided by clear guidelines on reimbursement, which are open and
understandable for professionals and insurance employees involved in the process.
A possibility might be to use existing practice guidelines as a platform. Insurances are not obliged
to reimburse practices which are recommended in guidelines. However, if resulting in better and more
efficient care, insurances should in their own interest support the implementation of (best practice)
guidelines. The NHS (National Health Service of England) proposes that with a standardised practice
related outcome evaluation (of orthotics) one could develop practical guidelines that could improve
quality of care and save money [70]. The impact of prosthetic guideline implementation has to be
evaluated in order to prove such claims [47]. Reimbursement decision (bodies) (in Germany G-BA
and GKV), practical guideline developers (clinicians and prosthetists) and HTA assessment bodies
are however separated [50] (p. 5). A closer collaboration might help in aligning best practice and
prescription guidelines with reimbursement decisions of insurances.
6. Conclusions and Future Research Directions
The reimbursement process in Germany may pose an insurmountable hurdle for people in need
of a prosthesis and decrease prosthesis acceptance and quality of life of users. Non-optimal prosthetic
care resulting from this may have negative impacts on social inclusion [12,13,18,27] and working
capabilities [38,64] (p. 114), thus having broader societal effects beyond the individual well-being.
Our analysis shows that prostheses are implicitly rationed to some extent, which contradicts German
disability law as well as BGB/SBG, which gives amputees the right to get the best available prosthesis
that may benefit them, according to their own subjective evaluation [62]. To overcome this issue,
regulatory changes, the development of adequate cost-effectiveness evaluation methods for medical
products (taking into account the “social side” of prosthetic care), and ethical discussions about the
justification of prioritisation or budget reallocations are needed. With our exemplary analysis of what
implicit rationing of health care may mean for individuals, we hope to contribute to the broader
discussion and to help raise public and political awareness for this pressing problem. More quantitative
and qualitative studies on reimbursement experiences and effects are needed.
Translational research requires (1) cooperation between the involved professions. Starting points
for tangible improvements, which may be promoted in CPGs, could be the (2) inclusion of research
findings in guidelines and (3) curricula for prosthetic technologists, both in order to more strongly
link academic research to practice. Furthermore, R&D should (4) be conducted in a user-centric way
from the early stages. This allows incorporating a social and personal experience perspective on the
technology, in addition to the instrumental and functionality-centred perspective developers have.
Empowerment of users through the chance of (5) individual choice of prostheses and (6) through
communication with peers and (7) prosthetists is also crucial, due to the complexity of prosthetic
care and individual preferences and needs. In order to make CPGs more inclusive and to adequately
incorporate social aspects in them, patient views need to be systematically included in the development
process. A further step would be to couple CPGs with reimbursement regulation.
We may draw several conclusions from our analysis. First, we posit that improvements in
prosthetic care that are based on insights from social science will decrease rather than further increase
pressure on the health care budget. This hypothesis should be tested in studies on prosthetic care
spending and on benefits for users by means, making use of HTA methods. The development of
adequate cost-effectiveness evaluation methods for medical products (taking into account the “social
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side” of prosthetic care) is a prerequisite for that. Much work has been conducted in this area and
discussions are ongoing, but there are still many open methodological and regulatory issues. In the
future, more encompassing studies on prosthetic care may be conducted, in order to evaluate prosthetic
devices but also organisational and social measures to improve prosthetic care (with respect to a
broader understanding of efficiency in activities of daily living).
HTA may help to make reimbursement decisions more transparent and based on evidence, e.g.,
also on quality of life gains through prosthetic technology. However, this requires new forms of
collaboration between HTA agencies and professionals and users in the field, new study designs
(focusing on real-world evidence and patient preferences), and of course, financial resources.
To start and guide an improvement process, the interests of all stakeholders should be taken into
account and ideally be discussed in a dialogic format. Some years ago, an attempt has already been
made to discuss reimbursement issues in a multi-stakeholder setting that included representatives of
insurances, producers, health economics, prosthetists, and doctors. However, it had a rather narrow
focus on a specific prosthetic leg model and had little tangible or broader impact so far [57]. In our
point of view, strong efforts should be made to continue with such processes, making it even more
inclusive by taking into account the users themselves as well as representatives from regulation and
health technology assessment.
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